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No Increased Bone Formation around Alendronate or Omeprazole
Loaded Bioactive Bone Cements in a Femoral Defect
ESTHER W.H. BODDE, M.D.,1 RICK S.Z. KOWALSKI, Ph.D.,2
PAUL H.M. SPAUWEN, M.D., Ph.D.,3 and JOHN A. JANSEN, D.D.S., Ph.D.1
ABSTRACT
Alendronate and omeprazole have been found to influence bone healing by interfering with osteoclastic
activity, resulting in increased bone formation. The biological effect of these conventional drugs, incorpo-
rated into bioactive bone cement (G2B1), was investigated in a rabbit model. The 2 materials and a control
were inserted in defects created in the femoral condyle of rabbits. Implantation time was 6 and 12 weeks.
After retrieval, micro-computed tomography and histomorphometry were performed to quantify bone
mineral density (BMD) and bone volume (BV) of the implant-surrounding bonemass and the percentage of
bone-to-implant contact. BMD and BV were similar in all groups. The percentage of bone-to-implant
contact was significantly lower in the alendronate and omeprazole groups than in controls after 6 weeks of
implantation. After 12 weeks, this difference in bone contact disappeared for the omeprazole but not for
the alendronate implants, which were almost completely surrounded by a fibrous capsule, associated with a
limited inflammatory response. In conclusion, in the current study, alendronate and omeprazole did not
result in better bone healing when incorporated into bioactive bone cement than did plain control implants.
Moreover, an additional cytotoxicity assay revealed that alendronate evoked a toxic response.
INTRODUCTION
BONE REMODELING IS based on the existence of a delicateequilibrium between bone deposition by osteoblasts
and bone resorption by osteoclasts.1–3 The regulation of this
complex process is dependent on the effect of local and
systemic factors on mesenchymal cells of the osteoblastic
lineage and hemopoietic precursors to form osteoclasts.4
An increase in bone formation can be achieved by influ-
encing 1 of the 2 mechanisms: bone formation or bone
resorption. Such an approach can be used for targeted ther-
apeutic interventions in bone diseases, which are associated
with bone loss, or for improvement in the bioactivity of
biomaterials used for bone replacement.
In view of this, bone cements can be applied as grafting
materials to obtain fracture stability or for the fixation of
prostheses.5–7 A strategy to improve the bone regenerative
properties of bone cements can be the incorporation of
biological active agents. A well-known example of this
approach is scaffolds provided with bone growth stimu-
lating factors,8,9 but the high costs of these growth factors
limit their wide clinical application. The use of relatively
inexpensive conventional pharmaceuticals, which can have
a local effect on the bone remodeling process, might
therefore be an alternative option. A class of pharmaceu-
ticals is available, including bisphosphonates and proton
pump inhibitors (PPIs), that have been found to interfere
with osteoclastic activity, inducing an increase in local
bone density. Osteoclasts resorb bone mineral because they
make an acidic extracellular environment in their ruf-
fled border zone through the action of so-called proton
pumps.
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Nitrogen-containing bisphosphonates such as alendro-
nate hamper osteoclastic bone resorption by inhibiting the
key enzyme farnesyl pyrophosphate synthetase, leading to
disruption of the organization of the cytoskeleton, which
causes inactivity and apoptosis of osteoclasts.10 These med-
icines are administered systemically to treat various dis-
eases associated with excessive bone resorption, including
Paget’s disease, myeloma, bone metastases, and osteopo-
rosis.11 However locally applied bisphosphonates have also
been shown to influence bone resorption.12–18 In addition to
the use of bisphosphonates, the activity of the proton pumps
can be directly targeted. Omeprazole is a gastric PPI used
for the treatment of acid-related diseases, including gas-
troesophageal reflux and peptic ulcer diseases.19 In addition
to the inhibition of gastric parietal cell membrane Hþ,
K(þ)-adenosine triphosphatase (ATPase), it is suggested
that this drug also inhibits the vacuolar-type H(þ)-ATPase
found in osteoclasts.20–24 These vacuolar proton pumps
play a role in the formation of an acidic environment in the
extracellular ruffled border zone of osteoclasts, which is
crucial for bone resorption.25,26
The present study examined whether the incorporation of
a bisphosphonate (alendronate) or a PPI (omeprazole) into
bioactive bone cement could result in an increase in local
bone density and bone-to-implant contact through inhibi-
tion of osteoclast activity.
MATERIALS AND METHODS
Materials
Bioactive bone cement that had previously been shown to
be biocompatible and osteoconductive27 was used as a carrier
material for the pharmaceuticals. DePuy CMW (Blackpool,
England) supplied bone cement (G2B1) composed of b-
tricalcium-phosphate (TCP) particles; methylmethacrylate-
methylacrylate copolymers as the powder components; and
methylmethacrylate, urethane dimethacrylate, and tetrahy-
drofurfuryl methacrylate as the liquid components.27 Three
types of implants were prepared out of this material (I¼
plain G2B1, II¼G2B1 with alendronate, and III¼G2B1
with omeprazole). Sodium alendronate or omeprazole was
mixed through the cement powder in a ratio of 4.76%, then
20 g of cement powder was mixed with 11.25 g of cement
liquid to create bone cement rods with a diameter of 5.1 mm
and a length of 8 mm. The total quantity for both types of
drugs in the cement was 3.05% by weight (*8.8 mg per
implant). The material was sterilized using gamma radiation
(Gammastar, Wageningen, the Netherlands).
Surgical procedure
Twenty-four healthy 7-month-old female New Zealand
White rabbits weighing 3976 332 g were included as
experimental animals in this study. National guidelines for
the care and use of laboratory animals were observed. The
Experimental Animal Committee of the Radboud Univer-
sity reviewed and approved the research.
The operation was performed under general inhalation
anesthesia. The anesthesia was induced using an intrave-
nous injection of Hypnorm (0.315 mg/mL fentanyl citrate
and 10 mg/mL fluanisone) ( Janssen Pharmaceutica, Beerse,
Belgium) and atropine and maintained using a mixture of
nitrous oxide, isoflurane, and oxygen through a constant
volume ventilator. The rabbits were connected to a heart
monitor. To reduce perioperative infection risk, antibiotic
prophylaxis was given (enrofloxacin 2.5%, 5–10 mg/kg;
Bayer Healthcare, Mijdrecht, the Netherlands).
The rabbits were immobilized on their backs and
both hind limbs were shaved, washed, and disinfected with
chlorhexidine. The femoral condyles were exposed through
a medial longitudinal incision. Trabecular bone defects
(5.1 mm in diameter and 8 mm in depth) were created in
both limbs under continuous saline cooling using a dental
bur (Elcomed 100, W&H Dentalwerk Buermoos GmbH,
Buermoos, Austria). First a 2.3-mm drill bit (Twist Tri-
Spade drill, DRIVA, Implacom BV, Garderen, The Neth-
erlands) was used as a pilot. Then the defect was gradually
enlarged until a final defect size of 5.1 mm was created. All
bits were fashioned with an 8-mm stop to ensure a defect
of precisely 8 mm in depth. Debris was removed using
irrigation with saline solution. A polymeric implant was
placed into each trabecular bone defect. Subsequently, the
wound was closed in layers using resorbable Vicryl 4-0
suture material ( Johnson & Johnson, St.Stevens-Woluwe,
Belgium). Implantation time was 6 or 12 weeks. The ani-
mals were randomly assigned to 1 of the 3 groups (n¼ 8 for
each implant and time period).
To minimize post-operative discomfort, Finadyne
(Schering-Plough, Segre, France) (1 mg/kg) was adminis-
tered intramuscularly peroperatively and was continued for
2 days after surgery. Some question about the use of this
non-steroidal anti-inflammatory drug in bone surgery ex-
ists, because bone repair could possibly be impaired,28 but
as in humans, these drugs are a standardized postoperative
regimen for pain relief,29 so administration in our experi-
mental animals was considered to be justified. The animals
were housed in conventional rabbit cages, which allowed
for unrestricted weight-bearing activity and were observed
for signs of pain, infection, and proper activity. At the end
of the implantation periods, the rabbits were killed using an
intravenous injection of pentobarbital (CEVA Sante Ani-
male BV, Libourne, France), and implants with surround-
ing tissue were retrieved for micro-computed tomography
(mCT) and histological evaluation.
Micro-computed tomography
After retrieval, the femoral condyles were fixed in
phosphate-buffered formaldehyde solution (pH 7.4) and
dehydrated in ethanol 70%. Three-dimensional mCT images
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were made to analyze the bone mineral density (BMD) and
bone volume (BV) of the implant-surrounding bone mass.
The specimens were wrapped in Parafilm M (Pechiney
Plastic Packaging, Chicago, IL) to prevent drying during
scanning. Then all samples were scanned at an energy of
101 kV and intensity of 96 mA with a resolution of 37.41 mm
pixel using an aluminum filter (1 mm) (Skyscan-1072
X-ray micro-tomograph, TomoNT version 3N.5, Skyscan,
Aartselaar, Belgium). In addition, calibration rods with stan-
dardized BMD were scanned as reference. Cone-Beam
reconstruction (version 2.15, Skyscan) was performed. All
scan and reconstruction parameters applied were identical
for all specimens and calibration rods.
The data were analyzed using a CT analyser (version 1.4,
Skyscan). The region of interest (ROI) was specified as an
annular area with a diameter of 0.85 mm surrounding the
implants over a length of 3 mm (Fig. 1) covering similar
areas located in trabecular bone and a small part protruding
in the medullary cavity. In this area, BMD and BV were
determined. BMD is defined as the amount of bone mineral
per unit volume of bone tissue (g/cm3). It was calibrated
using calibration rods with known BMD (0.25 g/cm3 and
0.75 g/cm3) and a Hounsfield Unit calibration to water and
air density. As advised by Skyscan, the mean (total) value
for density, which is an average of trabecular bone and bone
marrow, was used to represent the BMD of the trabecular
bone surrounding the implants. In addition, BV (mm3) was
expressed as a percentage of the total ROI volume.
Histological procedures
After mCT scanning, the condyles were cut into smaller
specimens suitable for histological processing. The speci-
mens were dehydrated in increasing ethanol concentrations
(70–100%), treated with acetone for 6 h, and embedded
(non-decalcified) in modified methylmethacrylate (MMA)
consisting of a mixture of 300 mL of MMA, 30 mL of di-
butylphthalate, and 5 g of 2,2’azabisisobutyronitrile 98%.
After polymerization, thin sections (7 mm) were cut in a di-
rection parallel to the longitudinal axis of the implant using
a rotary microtome with semi-motorized specimen feed and
profile D disposable blades (Leica RM 2245, Wetzlar,
Germany). The sections were stretched on 3% gelatin-
coated slides, dried for 48 hat 378C in a slide press, and
stained with tartrate-resistant acid phosphatase (TRAP). To
perform TRAP staining, the sections were first deplastified
with chloroform and xylene and rinsed in decreasing eth-
anol solutions and distilled water. Then the deplastified
sections were transferred into 0.2-M TRIS-magnesium
chloride (MgCl2) buffer (pH 9.0) for 2 h at 378C. After
rinsing with distilled water, the sections were incubated in
a solution consisting of hexazotized pararosaniline (4 mL),
naphthol AS-BI phosphate (25 mg), N,N-dimethylformamide
(2.5 mL), veronal buffer (12.5 mL), and MgCl2 (0.5 g) (pH
5.0) at 378C. Positive staining developed within 30 min.
Positive control sections were included.
Additional thicker sections (15–20 mm) were prepared in
a similar way using a modified sawing microtome tech-
nique. These sections were stained with methylene blue and
basic fuchsin and were used for histological evaluation and
histomorphometrical analysis.
Histomorphometrical analysis
All sections were quantitatively scored for the percentage
of bone-to-implant contact using computer-based image
analysis techniques (Leica Qwin Pro-image analysis system,
Wetzlar, Germany) and blinded for the reviewer. From
a transverse overview of the defect, 6 identical areas were
digitalized (magnitude 10) (Fig. 2). In these regions, the
amount of bone contact was determined, defined as the
length at which direct bone-to-implant contact was seen
without an intervening soft tissue layer. Bone contact was
then expressed as a percentage of the sum of bone contact in
the 6 areas to the entire implant length of these areas. The
measurements of 3 sections for each sample were averaged.
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FIG. 1. The region of interest as specified with computed tomography (CT) analyzer shown in a (A) longitudinal and (B) transverse
micro-CT image. Color images available online at www.liebertpub.com /ten.
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Statistics
All statistical analyses were performed with GraphPad
Instat 3.05 software (GraphPad Software Inc, San Diego,
CA), using a 1-way analysis of variance (ANOVA) and un-
paired t-test with Welch correction. Differences were con-
sidered significant at p-values less than 0.05.
RESULTS
Macroscopical evaluation
All rabbits endured the surgical procedure well and re-
mained in good health during the experimental periods. At
sacrifice, no signs of inflammation or adverse tissue reac-
tion were seen. Post-sacrifice radiographs as obtained with
mCT imaging revealed that the implants were located mostly
in trabecular bone (Fig. 3) and that this trabecular area was
similar between the different samples.
Micro-computed tomography
Three-dimensional mCT images were created to analyze
the BMD and BV of the implant-surrounding bone mass.
The results of the measurements are listed in Table 1. No
significant difference in BMD was found between the im-
plant types after 6 ( p¼ 0.12) or 12 weeks of implantation
( p¼ 0.31) (ANOVA). In addition, no significant difference
in BMD was seen between the 6- and 12-week groups
(unpaired t-test with Welch correction). The percentage of
BV in the ROI as determined using mCT was not signifi-
cantly different between the implant types after 6 ( p¼
0.18) and 12 weeks of implantation ( p¼ 0.42) (ANOVA).
Comparing 6 and 12 weeks of implantation time, alen-
dronate implants showed a trend ( p¼ 0.07) toward lower
BV after 12 weeks. In the omeprazole implants, BV was
significantly ( p¼ 0.008) lower after 12 weeks implantation
than after 6 weeks (unpaired t-test with Welch correction).
Descriptive light microscopy
Implantation time 6 weeks. The implant material was
clearly visible in the histological sections, showing b-TCP
particles embedded in the polymeric matrix. In all speci-
mens, the implants were found to be inserted and sur-
rounded by trabecular bone.
The plain control material was never associated with an
inflammatory response (Fig. 4A). The surface of the plain
control material was partly covered with a layer of bone.
Occasionally, new bone formation was associated with the
presence of osteoid lined with osteoblasts. There was tight
contact between the new bone and plain control surface
FIG. 2. Bone-to-implant contact was determined using histomor-
phometrical analysis in 6 identical areas covering the whole im-
plant surface. Color images available online at www.liebertpub
.com /ten.
FIG. 3. Post-sacrifice radiographs as obtained with micor-computed tomography imaging revealed that the implants were mainly
located in trabecular bone: (A) plain control, (B) alendronate, and (C) omeprazole implant.
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TABLE 1. THE BONE MINERAL DENSITY (BMD) AND PERCENTAGE OF BONE VOLUME (BV) IN THE REGION
OF INTEREST AS DETERMINED USING MICRO-COMPUTED TOMOGRAPHY
BMD (g/cm3) BV (%)
6 weeks 12 weeks 6 weeks 12 weeks
Mean Standard Deviation
Plain 0.71 0.03 0.74 0.07 15.5 2.6 13.7 2.7
Alendronate 0.76 0.06 0.76 0.06 18.3 3.9 14.8 2.6
Omeprazole 0.74 0.06 0.71 0.06 18.5 3.9 13.3 1.6{
No significant differences were found in BMD between the groups. BV was significantly ({) lower after 12 than after 6
weeks of implantation in the omeprazole implants.
FIG. 4. Histological sections after 6 weeks of implantation of (A) plain, (B) alendronate, and (C) omeprazole implants (higher mag-
nifications in (D, E, and F)). Methylene blue and basic fuchsin staining. Color images available online at www.liebertpub.com /ten.
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(Fig. 4D). No intervening fibrous tissue layer was present.
At trabecular voids and in areas where no bone contact was
seen, the implant surface was in direct contact with bone
marrow. No clear fibrous capsule was visible in these areas.
The alendronate and omeprazole implants, on the other
hand, showed a completely different bone response (Fig.
4B, C). These materials were mostly surrounded with a
fibrous tissue capsule, and only limited direct bone-implant
contact was observed (Fig. 4E, F). Fibrous tissue capsule
formation was associated with an inflammatory response in
trabecular void areas (Fig. 4E).
Implantation time 12 weeks. At 12 weeks of implanta-
tion, bone response to the plain control implants was sim-
ilar to that at 6 weeks. Bone remodeling had continued, and
bone appeared to be somewhat more mature. Between bone
and implant, close contact was still present (Fig. 5A). More-
over, bone was integrated into the superficial layer of the
material, indicating degradation of the outer implant sur-
face. Intermittently, resorption lacunae were present, charac-
terized by voids filled with osteoclast-like cells (Fig. 5A).
A fibrous tissue capsule, associated with a limited inflam-
matory response, almost completely surrounded the alen-
dronate implants (Fig. 5B).
The bone response to the omeprazole implants was differ-
ent at 6 weeks of implantation. Significantly more bone was
observed in tight contact with the implant surface (Fig. 5C).
In areas of tight contact, degradation of the outer implant
surface was seen. In areas not covered by bone, a thin fi-
brous capsule still surrounded the implants, although capsule
formation was no longer associated with an inflammatory
response.
TRAP staining. In all sections (i.e., for all implant for-
mulations and both implantation times), TRAP-positive
cells were present in the surrounding trabecular bone and at
the bone–implant interface (Fig. 6). TRAP staining was not
found to be specific to differentiate between osteoclasts,
macrophages, and giant cells. In addition, the aspecific mor-
phology of these interfacial cells excluded their proper
characterization. As a consequence, no correct quantification
was possible. Nevertheless, the number of TRAP-positive
cells was limited in the close vicinity of the implants, and no
clear difference between the 3 implant materials was seen.
Histomorphometry
Results of the bone-to-implant contact measurements are
presented in Table 2. Bone contact was significantly ( p¼
0.001) lower in the alendronate and omeprazole groups
than in the plain control implants after 6 weeks of implan-
tation (ANOVA). In the 12-week group, alendronate im-
plants had significantly ( p< 0.001, ANOVA) lower bone
contact than plain and omeprazole implants. Comparing
6 and 12 weeks implantation time, alendronate implants
FIG. 5. Histological sections after 12 weeks of implantation of
(A) plain, (B) alendronate, and (C) omeprazole implants. Methyl-
ene blue and basic fuchsin staining. Color images available online
at www.liebertpub.com /ten.
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showed a trend ( p¼ 0.07) toward less bone contact after 12
weeks, whereas in the omeprazole implants, the bone con-
tact increased significantly over time ( p¼ 0.008) (unpaired
t-test with Welch correction).
DISCUSSION
The local application of bone antiresorptive drugs is an
interesting approach to enhance the bone regenerative be-
havior of bone-replacing materials, compared, for instance,
with expensive growth factor inclusion. In the present
study, the bisphosphonate alendronate and the gastric pro-
ton pump inhibitor omeprazole were incorporated into
bioactive bone cement and examined for their positive ef-
fect on bone healing, but neither drug improved bone
healing over plain control implants.
One possible indication for the composite bone cement
(G2B1) is for percutaneous transpedicular vertebroplasty; a
previous animal study showed the biocompatible and osteo-
conductive properties of the material.27 The present study
confirmed this finding, because a reasonable amount of new
bone was tightly attached to the plain control implants after
6 weeks of implantation, which remained at 12 weeks. Ap-
parently, the inclusion of b-TCP particles improves the bone
response better than exclusively polymethylmethacrylate-
based materials, which is consistent with previous investiga-
tions studying calcium phosphate–based bone cements.30–33
In percutaneous transpedicular vertebroplasty, but also in
other orthopedic and dental procedures, it is important to
obtain optimal binding between bone and implanted ma-
terial. The inclusion of bone antiresorptive agents might
contribute to faster and enhanced ingrowth of new bone
into bone cement composites with greater bone density in
the implant surroundings. Topical application of these bone-
stimulating agents might be preferable to a systemic route,
because negative side effects at locations remote from the
defect area might be prevented.
The current study had several limitations. First, only one
dose of alendronate and omeprazole was incorporated into
the bone cement. The method of inclusion and the dosage
were based on previous studies by other investigators, who
proved that the inclusion of 3 to 4 wt% of gentamycin and
alendronate did not affect the mechanical or setting prop-
erties of acrylic cement.34,35 Second, the elution of the in-
cluded pharmaceuticals from the cured cement was not
investigated. This was decided because other studies in our
laboratory confirmed that in vitro release assays provide
completely different results from the in vivo situation,36 and
in our laboratory, no method was available to determine the
in vivo release of alendronate and omeprazole. However,
we suppose that the mechanism of elution of both phar-
maceuticals will be similar to the elution of antibiotics from
an antibiotic-loaded acrylic bone cement (i.e., a surface phe-
nomenon).37 Third, no assays were performed to verify the
mode of action and cellular uptake of the released alen-
dronate and omeprazole. Such tests were out of the scope of
the current study, in which we only wanted to prove the
occurrence of a clinical effect of local delivery of both
pharmaceuticals by inclusion in bone cement. Nevertheless,
we must emphasize that measures were taken to maintain
the bone cement at 378C to 408C during the curing process
in order not to hamper the activity of the alendronate and
omeprazole.
Alendronate, as a nitrogen-containing bisphosphonate, is
known to inhibit osteoclastic bone resorption by inhibition
of a key enzyme of the mevalonate pathway when admin-
istered systemically.10 In this way, the lack of this enzyme
will dominate the bone repair equilibrium of bone resorption
and formation. It can be hypothesized that the topical ap-
plication of alendronate will modify the local osteoclastic
activity and thereby slow down the bone resorption during
initial remodeling,12 leading to better bone formation around
the implant, although in the present study, topically applied
alendronate did not enhance the local bone conditions around
FIG. 6. Tartrate-resistant acid phosphatase–positive cells at the
interface of a plain control implant after 6 weeks of implantation.
Color images available online at www.liebertpub.com /ten.
TABLE 2. THE PERCENTAGE OF BONE-TO-IMPLANT CONTACT
AS DETERMINED USING HISTOMORPHOMETRY
Bone contact (%) Mean Standard Deviation
6 weeks 12 weeks
Plain 37.6 10.1* 36.1 18.4
Alendronate 11.9 10.6 3.7 4.7**
Omeprazole 19.6 14.6 39.3 9.4{
In the 6-week group, bone contact was significantly (*) higher in the plain
implants than in the alendronate and omeprazole groups. After 12 weeks, the
alendronate implants showed significantly (**) less bone contact than the
other groups. In the omeprazole implants, the bone contact increased sig-
nificantly over time ({).
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G2B1 cement or the bone-to-implant contact more than did
the plain control samples. Moreover, a negative response
was seen, because the contact between cement and bone
was significantly lower than with the control material, and a
fibrous capsule associated with an inflammatory infiltrate
mainly covered the cement surface. Nevertheless, bispho-
sphonates have been shown to affect bone formation in
several studies when applied locally. This included greater
bone contact, peri-implant BV or density fractions, and
biomechanical implant fixation in rat16,38–40 and canine
models.13–15,17,18 Similar results in osteoconduction and
alveolar bone repair were found between loaded and un-
loaded bisphosphonate–hydroxyapatite implants placed in
root sockets of goats and humans.41 An explanation for the
limited bone response as found in the current study might be
too-high doses of alendronate being used in combination
with the mode of delivery. Unfortunately, a direct compar-
ison between the different studies is not possible because of
dissimilar animal species and study design, such as mode of
delivery. Peter et al.,16 who revealed that intermediate doses
of zoledronate achieved the greatest mechanical fixation of
hyaluronic acid–coated titanium implants placed in rat
condyles, showed a dose-dependent effect of locally re-
leased bisphosphonate. It has been suggested that high doses
of alendronate impair the bone repair process by uncoupling
the balanced osteoclastic and osteoblastic activity42,43 or
increasing local acidity and thereby interfering with anti-
resorptive activity.39 In addition, non-therapeutic doses of
alendronate can cause a toxic reaction,44 which the forma-
tion of a fibrous tissue capsule and inflammatory response
supports. Therefore, we performed an additional cytotoxic-
ity assay with materials prepared in the same way as used in
the animal study to verify this suggestion. This test revealed
cell death of fibroblasts surrounding alendronate specimens
after 72 h of incubation (Fig. 7B), similar to a negative
control of brass. In contrast, confluent fibroblasts in close
contact to the material were found around plain and ome-
prazole specimens (Fig. 7A/C). Although fibroblastic cell
death can also be related to the working mechanism of
alendronate, as was seen for gastrointestinal epithelial
cells,45 it must be considered that the sample formulations
used in the present study had a noxious effect.
An additional explanation for impaired bone healing
after bisphosphonate treatment involves a clinical problem
that has remained largely unexplored for a long time. Re-
cent publications have described a greater risk of develop-
ing osteonecrosis associated with bisphosphonate therapy
and dental surgery.46–49 The pathophysiology behind the
process has not been completely elucidated, but it is prob-
ably multifactorial and related to an alteration in the bone
homeostasis and inhibition of angiogenesis.47–51 Because
surgical intervention seems to be obligatory in the devel-
opment of the majority of the osteonecrosis cases,47,48 it is
conceivable that, in the present study, the combination of
creating a bone defect and applying alendronate also evoked
a negative bone response.
FIG. 7. The results of a cytotoxicity assay showing fibroblastic
cells surrounding (A) plain, (B) alendronate, and (C) omeprazole
bioactive bone cements after 72 h of incubation. Cell death was
seen in the alendronate group. Color images available online at
www.liebertpub.com /ten.
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In addition to alendronate, omeprazole was investigated
as a possible bone antiresorptive agent in the G2B1 cement
composites. In the clinic, omeprazole is used to treat dys-
peptic problems, because it inhibits gastric acid secretion
by targeting the gastric acid pump Hþ,K(þ)-ATPase of the
parietal cell membrane.19 Osteoclastic bone resorption is
also regulated via a proton pump but of a different type
than with gastric acid secretion. This vacuolar-type Hþ
-ATPase generates acidity in the ruffled border zone of the
osteoclast, which is responsible for bone resorption.25,26
In the present study, it was hypothesized that topically
applied omeprazole could inhibit the osteoclastic proton
pump, leading to greater bone formation in G2B1 cement
composites in rabbits, because previous in vitro studies
showed that this gastric PPI could affect osteoclast activ-
ity,20,21,23,24 but omeprazole did not influence BV or BMD
around the implanted material, and bone contact was sig-
nificantly lower in the omeprazole group than in plain
controls after 6 weeks and was similar after 12 weeks of
implantation. This observation may be associated with the
finding that osteoclastic proton pumps are not sensitive for
gastric PPIs and require high doses of omeprazole to be
suppressed.20,24 In addition, to become activated, omepra-
zole first needs to be converted into an active inhibitor in an
acidic environment.20,22,52 Tutunji et al.52 showed, using
electroanalytical techniques, that in a solution buffered to
pH values between 5.0 and 8.0, omeprazole degradation
was significantly slower than more acidic solutions with a
pH of 2.0 to 4.0. The secretory canaliculi of the gastric
parietal cells have a pH of 1.0 or less,52 whereas resorption
lacunae of bone have a pH of 4.5 to 6,20,26 which theoret-
ically can hamper the initial omeprazole conversion. In the
present study, these above-described factors of limited
omeprazole availability and the inability of activation due
to unfavorable acidity might have played a role in the sug-
gested hindered osteoclast inhibition as found in the ome-
prazole group.
In addition to experimental animal studies, a few clinical
investigations have been performed on the topic of influ-
encing bone formation with omeprazole treatment and also
showed contradictory results. Kocsis et al.53 did not find
different biochemical parameters of bone turnover in pe-
diatric patients after omeprazole administration, which is in
line with our results. On the other hand, a favorable bone
response of omeprazole administration was seen in the
study of Mizunashi et al.,22 who showed a suppression in
bone resorption in adult patients treated with gastric PPIs.
Although the current study did not find positive effects of
local administration of alendronate or omeprazole, the study
design might explain this. As mentioned earlier, a limita-
tion of the present study was the lack of in vivo release data.
Comparing the mCT results, BV surrounding the omepra-
zole implants was significantly lower after 12 weeks than
after 6 weeks of implantation, and a similar trend was seen
for the alendronate implants. In addition, the plain implants
showed a trend toward less BV than with alendronate or
omeprazole after 6 weeks of implantation. It can be spec-
ulated that both drugs had an early (burst) release profile
leading to an increase in bone formation in the first weeks
and diminished bone response after 12 weeks of implan-
tation. Future studies should focus on the in vivo release
profiles of both pharmaceuticals and their dose responses to
further examine the possibility of topical instead of sys-
temic application to provide bone-regenerative biomaterials
with targeted antiresorptive agents.
CONCLUSION
Plain G2B1 bone cement composites showed good bone
biological response in rabbit trabecular defects. Alendro-
nate and omeprazole as applied to the cement composites in
the current study design did not improve the bone response.
Moreover, the released alendronate might have evoked a
toxic reaction.
ACKNOWLEDGMENTS
This study was financially supported by DePuy CMW.
The authors would like to thank Ms. M. van der Zande for
her assistance with the cytotoxicity assay.
REFERENCES
1. Stains, J.P. and Civitelli, R. Cell-to-cell interactions in bone.
Biochem Biophys Res Commun 328, 721, 2005.
2. Martin, T.J. and Sims, N.A. Osteoclast-derived activity in the
coupling of bone formation to resorption. Trends l Med 11,
76, 2005.
3. Katagiri, T. and Takahashi, N. Regulatory mechanisms of os-
teoblast and osteoclast differentiation. Oral Dis 8, 147, 2002.
4. Raisz, L.G. Physiology and pathophysiology of bone re-
modeling. Clin Chem 45, 1353, 1999.
5. Kenny, S.M. and Buggy, M. Bone cements and fillers: a re-
view. J Mater Sci Mater Med 14, 923, 2003.
6. Heini, P.F. and Berlemann, U. Bone substitutes in vertebro-
plasty. Eur Spine J 10 Suppl 2, 205, 2001.
7. Larsson, S. and Bauer, T.W. Use of injectable calcium
phosphate cement for fracture fixation: a review. Clin Orthop
Relat Res 395, 23, 2002.
8. Wozney, J.M. Overview of bone morphogenetic proteins.
Spine 27, S2, 2002.
9. Jansen, J.A., Vehof, J.W., Ruhe, P.Q., Kroeze-Deutman, H.,
Kuboki, Y., Takita, H., Hedberg, E.L. and Mikos, A.G.
Growth factor-loaded scaffolds for bone engineering. J Con-
trol Release 101, 127, 2005.
10. van Beek, E.R., Cohen, L.H., Leroy, I.M, Ebetino, F.H.,
Lowik, C.W., and Papapoulos, S.E. Differentiating the mech-
anisms of antiresorptive action of nitrogen containing bisphos-
phonates. Bone 33, 805, 2003.
11. Russell, R.G. Bisphosphonates: from bench to bedside. Ann N
Y Acad Sci 1068, 367, 2006.
BONE FORMATION AROUND BIOACTIVE BONE CEMENTS 37
12. McLeod, K., Anderson, G.I., Dutta, N.K., Smart, R.St.C.,
Voelcker, N.H., Sekel, R., and Kumar, S. Adsorption of bispho-
sphonate onto hydroxyapatite using a novel co-precipitation
technique for bone growth enhancement. J Biomed Mater Res
A 79, 271, 2006.
13. Jakobsen, T., Kold, S., Bechtold, J.E., Elmengaard, B., and
Soballe, K. Local alendronate increases fixation of implants
inserted with bone compaction: 12-week canine study. J Or-
thop Res 25, 432, 2007.
14. Jakobsen, T., Kold, S., Bechtold, J.E., Elmengaard, B., and
Soballe, K. Effect of topical alendronate treatment on fixation
of implants inserted with bone compaction. Clin Orthop Relat
Res 444, 229, 2006.
15. Tanzer, M., Karabasz, D., Krygier, J.J., Cohen, R., and Bo-
byn, J.D. The Otto Aufranc Award: bone augmentation
around and within porous implants by local bisphosphonate
elution. Clin Orthop Relat Res 441, 30, 2005.
16. Peter, B., Pioletti, D.P., Laib, S., Bujoli, B., Pilet, P., Janvier,
P., Guicheux, J., Zambelli, P.-Y., Bouler, J.-M., and Gauthier,
O. Calcium phosphate drug delivery system: influence of
local zoledronate release on bone implant osteointegration.
Bone 36, 52, 2005.
17. Meraw, S.J. and Reeve, C.M. Qualitative analysis of periph-
eral peri-implant bone and influence of alendronate sodium on
early bone regeneration. J Periodontol 70, 1228, 1999.
18. Meraw, S.J., Reeve, C.M., and Wollan, P.C. Use of alen-
dronate in peri-implant defect regeneration. J Periodontol 70,
151, 1999.
19. Horn, J. The proton-pump inhibitors: similarities and differ-
ences. Clin Ther 22, 266, 2000.
20. Mattsson, J.P., Vaananen, K., Wallmark, B., and Lorentzon,
P. Omeprazole and bafilomycin, two proton pump inhibitors:
differentiation of their effects on gastric, kidney and bone
H(þ)-translocating ATPases. Biochim Biophys Acta 1065,
261,1991.
21. Zaidi, M. Modularity of osteoclast behaviour and ‘‘mode-
specific’’ inhibition of osteoclast function. Biosci Rep 10,
547, 1990.
22. Mizunashi, K., Furukawa, Y., Katano, K., and Abe, K. Effect
of omeprazole, an inhibitor of Hþ,K(þ)-ATPase, on bone
resorption in humans. Calcif Tissue Int 53, 21, 1993.
23. Tuukkanen, J. and Vaanane, H.K. Omeprazole, a specific
inhibitor of Hþ-Kþ-ATPase, inhibits bone resorption in vitro.
Calcif Tissue Int 38, 123, 1986.
24. Hall, T.J. and Chambers, T.J. Naþ/Hþ antiporter is the pri-
mary proton transport system used by osteoclasts during bone
resorption. J Cell Physiol 142, 420, 1990.
25. Rousselle, A.V. and Heymann, D. Osteoclastic acidification
pathways during bone resorption. Bone 30, 533, 2002.
26. Vaes, G. Cellular biology and biochemical mechanism of
bone resorption. A review of recent developments on the
formation, activation, and mode of action of osteoclasts. Clin
Orthop Relat Res 231, 239, 1988.
27. Goto, K., Shinzato, S., Fujibayashi, S., Tamura, J., Kawanabe,
K., Hasegawa, S., Kowalski, R., and Nakamura, T. The bio-
compatibility and osteoconductivity of a cement containing
beta-TCP for use in vertebroplasty. J Biomed Mater Res A 78,
629, 2006.
28. Aspenberg, P. Drugs and fracture repair. Acta Orthop 76, 741,
2005.
29. Bourne, M.H. Analgesics for orthopedic postoperative pain.
Am J Orthop 33, 128, 2004.
30. Ooms, E.M., Wolke, J.G., van der Waerden, J.P., and Jansen,
J.A. Trabecular bone response to injectable calcium phos-
phate (Ca-P) cement. J Biomed Mater Res 61, 9, 2002.
31. Fini, M., Giavaresi, G., Aldini, N.N., Torricelli, P., Botter, R.,
Beruto, D., and Giardino, R. A bone substitute composed of
polymethylmethacrylate and alpha-tricalcium phosphate: re-
sults in terms of osteoblast function and bone tissue forma-
tion. Biomaterials 23, 4523, 2002.
32. Collinge, C., Merk, B., and Lautenschlager, E.P. Mechanical
evaluation of fracture fixation augmented with tricalcium
phosphate bone cement in a porous osteoporotic cancellous
bone model. J Orthop Trauma 21, 124, 2007.
33. Verlaan, J. J., Oner, F. C., Slootweg, P. J., Verbout, A. J., and
Dhert, W. J. Histologic changes after vertebroplasty. J Bone
Joint Surg Am 86-A, 1230, 2004.
34. Lewis, G., Janna, S., and Bhattaram, A. Influence of the
method of blending and antibiotic powder with an acrylic
bone cement powder on physical, mechanical, and thermal
properties of the cured cement. Biomaterials 26, 4317, 2005.
35. Lewis, G. and Janna, S. Alendronate in bone cement. Clin
Orthop Reat Res 445, 233, 2006.
36. Ruhe, P.Q., Boerman, O.C., Russell, F.G.M., Spauwen, P.H.M.,
Mikos, A.G., and Jansen, J.A. Controlled release of rhBMP-2
loaded poly(DL-lactic-co-glycolic acid)/calcium phosphate
cement composites in vivo. J Control Rel, 106, 162, 2005.
37. Lewis G. and Janna S. The in vitro evaluation of gentamycin
sulfate form a commercially available gentamycin-loaded
acrylic bone cement, VersaBond TM AB. J Biomed Mater
Res Part B Appl Biomater 71B, 77, 2004.
38. Astrand, J. and Aspenberg, P. Topical, single dose bispho-
sphonate treatment reduced bone resorption in a rat model for
prosthetic loosening. J Orthop Res 22, 244, 2004.
39. Binderman, I., Adut, M., and Yaffe, A. Effectiveness of
local delivery of alendronate in reducing alveolar bone loss
following periodontal surgery in rats. J Periodontol 71, 1236,
2000.
40. Aspenberg, P. and Astrand, J. Bone allografts pretreated with
a bisphosphonate are not resorbed. Acta Orthop Scand 73, 20,
2002.
41. Denissen, H., Montanari, C., Martinetti, R., van Lingen, A.,
and van den Hooff, A. Alveolar bone response to submerged
bisphosphonate-complexed hydroxyapatite implants. J Peri-
odontol 71, 279, 2000.
42. Lehman, R.A. Jr, Kuklo, T.R., Freedman, B.A., Cowart, J.R.,
Mense, M.G., and Riew, K.D. The effect of alendronate
sodium on spinal fusion: a rabbit model. Spine J 4, 36,
2004.
43. Sama, A.A., Khan, S.N., Myers, E.R., Huang, R.C., Cammisa,
F.P., Sandhu, H.S., and Lane, J.M. High-dose alendronate
uncouples osteoclast and osteoblast function: a study in a rat
spine pseudarthrosis model. Clin Orthop Relat Res 425, 135,
2004.
44. Marshall, J.K. The gastrointestinal tolerability and safety of
oral bisphosphonates. Expert Opin Drug Saf 1, 71, 2002.
45. Suri, S., Monkkonen, J., Taskinen, M., Pesonen, J.,
Blank, M.A., Phipps, R.J., and Rogers, M.J. Nitrogen-
containing bisphosphonates induce apoptosis of Caco-2 cells
in vitro by inhibiting the mevalonate pathway: a model of
38 BODDE ET AL.
bisphosphonate-induced gastrointestinal toxicity. Bone 29,
336, 2001.
46. Carter, G., Goss, A.N., and Doecke, C. Bisphosphonates and
avascular necrosis of the jaw: a possible association. Med J
Aust 182, 413, 2005.
47. Melo, M.D. and Obeid, G. Osteonecrosis of the jaws in pa-
tients with a history of receiving bisphosphonate therapy: strat-
egies for prevention and early recognition. J Am Dent Assoc
136, 1675, 2005.
48. Dimitrakopoulos, I., Magopoulos, C., and Karakasis, D.
Bisphosphonate-induced avascular osteonecrosis of the jaws:
a clinical report of 11 cases. Int J Oral Maxillofac Surg 35,
588, 2006.
49. Ruggiero, S.L., Mehrotra, B., Rosenberg, T.J., and Engroff,
S.L. Osteonecrosis of the jaws associated with the use of
bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg
62, 527, 2004.
50. Migliorati, C.A., Schubert, M.M., Peterson, D.E., and Seneda,
L.M. Bisphosphonate-associated osteonecrosis of mandibular
and maxillary bone. Cancer 104, 83, 2005.
51. Hasmim, M., Bieler, G., and Ruegg, C. Zoledronate inhibits
endothelial cell adhesion, migration and survival through the
suppression of multiple, prenylation-dependent signaling path-
ways. J Thromb Haemost 5, 166, 2007.
52. Tutunji, M.F., Qaisi, A.M., El-Eswed, B.I., and Tutunji, L.F.
Reactions of sulfenic acid with 2-mercaptoethanol: a mech-
anism for the inhibition of gastric (Hþ-Kþ)-adenosine tri-
phosphate by omeprazole. J Pharm Sci 96, 196, 2007.
53. Kocsis, I., Arato, A., Bodanszky, H., Szonyi, L., Szabo, A.,
Tulassay, T., and Vasarhelyi, B. Short-term omeprazole
treatment does not influence biochemical parameters of bone
turnover in children. Calcif Tissue Int 71, 129, 2002.
Address reprint requests to:
John A. Jansen, D.D.S., Ph.D.
Professor
Department of Periodontology and Biomaterials
Radboud University Nijmegen Medical Center
P.O. Box 9101, 6500 HB Nijmegen
The Netherlands
E-mail: j.jansen@dent.umcn.nl
BONE FORMATION AROUND BIOACTIVE BONE CEMENTS 39

This article has been cited by:
1. J.J. Verlaan, M.A. Lopez-Heredia, J. Alblas, F.C. Oner, J.A. Jansen, W.J.A. DhertInjectable Bone Cements for Spinal Column
Augmentation: Materials for Kyphoplasty/Vertebroplasty 147-160. [CrossRef]
2. Jessica A. Cottrell, Francis M. Vales, Deborah Schachter, Scott Wadsworth, Rama Gundlapalli, Rasesh Kapadia, J. Patrick
O'Connor. 2010. Osteogenic Activity of Locally Applied Small Molecule Drugs in a Rat Femur Defect Model. Journal of
Biomedicine and Biotechnology 2010, 1-12. [CrossRef]
3. Seung-Jun Ku, Young-Il Chang, Chang-Hoon Chae, Seong-Gon Kim, Young-Wook Park, Youn-Kwan Jung, Je-Yong Choi.
2009. Static tensional forces increase osteogenic gene expression in three-dimensional periodontal ligament cell culture. BMB
Reports 42:7, 427-432. [CrossRef]
